KRAS and cancer: In clinical applications, nanoparticle albumin-conjugated paclitaxel (nab-paclitaxel, nab-PTX) has been successfully used for targeted therapy of KRAS-mutant cancers (e.g., pancreatic cancer and breast cancer) [82].